We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Novel Liquid Biopsy Method for Detection of Cancer MicroRNA Biomarkers

By LabMedica International staff writers
Posted on 30 Dec 2019
The potential usefulness of the “liquid biopsy” approach for detection of cancer biomarkers in the blood has been increased by the development of a method for capturing and counting cancer-associated microRNAs.

MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. More...
With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions.

Highly selective and sensitive detection of microRNAs is a key challenge for those interested in developing liquid-biopsy approaches. Technologies that can achieve high diagnostic performance without the requirement of complicated processing steps or expensive equipment will be necessary for the technique to be available for general clinical use.

With these features in mind, investigators at the University of Illinois (Urbana-Champaign, USA) developed a digital-readout microRNA diagnostic procedure that relied on microRNA-activated nanoparticle-photonic crystal hybrid coupling. This procedure, which they called PRAM (Photonic Resonator Absorption Microscopy) was designed for the capture and quantification of microRNA biomarkers in samples of blood or serum.

PRAM works by combining a gold nanoparticle probe with a photonic crystal sensor. The probe specifically pairs to a designated microRNA and has a protective cap that becomes displaced when the molecule locates and binds to the target biomarker. The exposed end of the probe then binds to the photonic crystal (PC) biosensor surface. By matching the surface plasmon-resonant wavelength of the nanoparticle probe to the resonant wavelength of the PC nanostructure, the reflected light intensity from the PC is dramatically and locally quenched by the presence of each individual nanoparticle, each positive response produces a signal visible through a microscope.

Results obtained by the PRAM method showed that the procedure was sensitive enough to detect minute amounts of microRNA biomarkers present in a patient's serum while being selective enough to detect the specific marker among the immense number of other molecules that were also present in serum.

"Cancer cells contain gene mutations that enable them to proliferate out of control and to evade the immune system, and some of those mutations turn up in microRNAs," said senior author Dr. Brian Cunningham, professor of electrical and computer engineering at the University of Illinois. "There are specific microRNA molecules whose presence and concentration is known to be related to the presence and aggressiveness of specific types of cancer, so they are known as biomarkers that can be the target molecule for a diagnostic test."

"This approach makes the idea of performing a “liquid biopsy” for low-concentration cancer-related molecules a step closer to reality," said Dr. Cunningham. "This advance demonstrates that it is possible to have an inexpensive and routine method that is sensitive enough to require only a droplet of blood. The results of the test might tell a physician whether a regimen of chemotherapy is working, whether a person's cancer is developing a new mutation that would make it resistant to a drug, or whether a person who had been previously treated for cancer might be having a remission."

Details of the PRAM procedure were published in the September 24, 2019, issue of the journal Proceedings of the [U.S.] National Academy of Sciences.

Related Links:
University of Illinois


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.